Synopsis
Interpret benign breast pathology as a spectrum of future risk, distinguish proliferation without atypia from atypical hyperplasia and lobular neoplasia, and connect diagnosis to individual surveillance and prevention decisions.
- Benign breast disease is not one risk category: non-proliferative change, proliferative disease without atypia, atypical ductal or lobular hyperplasia and lobular carcinoma in situ carry different implications.
- Atypical hyperplasia is both a marker of elevated future bilateral risk and a possible incompletely sampled neighbour of carcinoma, so immediate lesion concordance and long-term risk assessment are separate questions.
- Lobular neoplasia may be incidental and multifocal; classical and pleomorphic forms do not share identical management, and the imaging target must be explained.
Reasoning priorities
Identify the exact proliferative diagnosis, atypia, extent in cores and any features requiring complete excision.
Benign is insufficient shorthand. Confirm whether the report describes usual hyperplasia, atypical ductal hyperplasia, lobular neoplasia, radial scar, papilloma or another B3 entity.
Worked reasoning
A fictional teaching case describes a 52-year-old postmenopausal woman whose 14 mm calcification cluster is completely removed by vacuum-assisted excision; final histology shows ADH only, with no DCIS or invasive carcinoma.
- At multidisciplinary review, confirm specimen radiography retrieved the calcification, post-procedure imaging shows no residual target, and pathology is concordant ADH without carcinoma. The current B3 lesion is therefore closed rather than treated as cancer.
- The risk clinic verifies a pedigree containing one mother diagnosed at 48 and a maternal aunt at 57, confirms no known pathogenic variant or prior breast cancer, and documents a 19% lifetime estimate using its stated validated method. This supplied fictional result falls in NICE's moderate 17% to under 30% category; it is not an author-performed model calculation.
- After discussing that current NHSBSP guidance permits routine screening following a non-upgraded, completely removed B3 target, she chooses the separate NICE moderate familial-risk option of annual mammography for the rest of ages 50 to 59. The regional familial-risk service accepts responsibility and books her next mammogram for 12 months after the completing VAE.
- After confirming postmenopausal status, no severe osteoporosis, baseline bone assessment and no conflicting oestrogen therapy, the patient chooses anastrozole 1 mg by mouth once daily for 5 years through an experienced prescriber and shared-care plan.
- The record now contains the no-residual-target MDT outcome, the supplied 19% estimate and assumptions, and the familial-risk service's annual-mammography booking. Baseline DXA shows a T-score of -1.1, so the shared-care prescriber dispenses anastrozole with a 5-year stop date; at the planned 8-week review she reports daily adherence and no new limiting adverse effect, and continuation with the documented bone-health plan is confirmed.
Key medicines
AnastrozoleFor primary prevention in an appropriately selected postmenopausal woman at moderate or high breast-cancer risk: 1 mg by mouth once daily for 5 years under an experienced prescriber and shared-care arrangement.Do not use in pregnancy, breastfeeding or premenopausal women, and do not combine with tamoxifen or oestrogen-containing therapy. Assess fracture and bone-mineral-density risk before and during treatment; severe osteoporosis makes it unsuitable in the NICE prevention pathway, and cardiovascular, joint and menopausal adverse effects require review.
TamoxifenFor primary prevention in an appropriately selected woman at moderate or high breast-cancer risk: 20 mg by mouth once daily for 5 years under an experienced prescriber and shared-care arrangement.For prevention, avoid with a history of deep-vein thrombosis or pulmonary embolism, increased thromboembolic or endometrial-cancer risk, pregnancy, or concurrent coumarin anticoagulants; do not combine with anastrozole. Exclude pregnancy before treatment and use barrier or other adequate non-hormonal contraception while sexually active; do not attempt conception during treatment or for 2 months after stopping. Tamoxifen is not recommended during breastfeeding. Avoid potent CYP2D6 inhibitors such as paroxetine, fluoxetine or bupropion where possible through prescriber-led medication review. Check QT-prolonging combinations and use electrolyte and ECG assessment for patients with QT risk factors rather than testing everyone. Discuss uterine bleeding and VTE symptoms and stop at least 6 weeks before elective surgery.